[Consequeces of the elimination of a combination drug. Transition from combination antisacer: attention].
Antisacer compositum, a commonly prescribed speciality which associated phenobarbitone and phenytoin in a dose ratio of 1:4, was withdrawn after demonstration of a negative interaction of this formula. A retrospective analysis is presented of phenytoin plasma levels during bitherapy and after passage to monotherapy, in 13 adult epileptics followed as outpatients. Phenytoin plasma levels increased over twofold in 12 cases, of whom 5 continued to take the same doses, while 7 received higher doses on, and in one case two weeks after, the withdrawal of phenobarbitone. Plasma level decreased slightly in the thirteenth in spite of increased doses. Five phenytoin intoxications occurred after this change of prescription: one amongst the 5 cases with identical doses, and 4 amongst the 7 cases with increased doses. The initially high levels of phenytoin tend to decrease after several months. Physicians required to change the prescription should be aware of the risk of initial intoxication and later underdosage.
D000328:Adult; D004338:Drug Combinations; D004827:Epilepsy / Q000188:drug therapy*; D006801:Humans; D010634:Phenobarbital / Q000627:therapeutic use*; D010672:Phenytoin / Q000097:blood / Q000627:therapeutic use* / Q000633:toxicity
D004338:Drug Combinations; D010672:Phenytoin; D010634:Phenobarbital
Les conséquences de l'élimination d'un médicament combiné.